[go: up one dir, main page]

WO2014115169A3 - Crizotinib solid dispersion - Google Patents

Crizotinib solid dispersion Download PDF

Info

Publication number
WO2014115169A3
WO2014115169A3 PCT/IN2014/000052 IN2014000052W WO2014115169A3 WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3 IN 2014000052 W IN2014000052 W IN 2014000052W WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3
Authority
WO
WIPO (PCT)
Prior art keywords
crizotinib
present
solid dispersion
preparation
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000052
Other languages
French (fr)
Other versions
WO2014115169A2 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Thungathurthy Srinivasa Rao
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014115169A2 publication Critical patent/WO2014115169A2/en
Anticipated expiration legal-status Critical
Publication of WO2014115169A3 publication Critical patent/WO2014115169A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a compound of crizotinib oxalate salt, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel process for the preparation of crizotinib using novel intermediate. The present invention further provides a process for the purification of crizotinib. The present invention further provides a novel amorphous solid dispersion of crizotinib in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
PCT/IN2014/000052 2013-01-24 2014-01-23 Crizotinib solid dispersion Ceased WO2014115169A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN329/CHE/2013 2013-01-24
IN329CH2013 2013-01-24

Publications (2)

Publication Number Publication Date
WO2014115169A2 WO2014115169A2 (en) 2014-07-31
WO2014115169A3 true WO2014115169A3 (en) 2016-02-25

Family

ID=51228161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000052 Ceased WO2014115169A2 (en) 2013-01-24 2014-01-23 Crizotinib solid dispersion

Country Status (1)

Country Link
WO (1) WO2014115169A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919866A (en) * 2022-12-07 2023-04-07 深圳海王医药科技研究院有限公司 Tepontinib solid dispersion and preparation method thereof
CN115887406B (en) * 2022-12-24 2024-02-13 山东理工职业学院 A kind of preparation method of crizotinib capsule
CN116688139B (en) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 Crizotinib pharmaceutical composition, and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
US7858643B2 (en) * 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858643B2 (en) * 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONING ET AL.: "Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066", ORG. PROCESS RES. DEV., vol. 15, no. 5, 2011, pages 1018 - 1026, XP055078841, DOI: doi:10.1021/op200131n *

Also Published As

Publication number Publication date
WO2014115169A2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
MX2013012542A (en) Amide compound and pharmaceutical application therefor.
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
HK1206028A1 (en) Phenicol antibacterials
MX2021011906A (en) Delayed release compositions of linaclotide.
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2014153495A9 (en) Novel stat3 inhibitors
IL241038B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2015092810A3 (en) Amorphous form of idelalisib
MX363530B (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
WO2015002755A3 (en) Compounds for the treatment of malaria
HK1212978A1 (en) Novel derivatives of sinapinic acid
WO2014115169A3 (en) Crizotinib solid dispersion
WO2014009970A3 (en) Linagliptin solid dispersion
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
IN2012CH01309A (en)
WO2014105777A8 (en) Cobicostat dichlohydrate salt
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14743833

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14743833

Country of ref document: EP

Kind code of ref document: A2